Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Monitoring New Long-Lasting Intravitreal Formulation for Glaucoma with Vitreous Images Using Optical Coherence Tomography

Maria Jesus Rodrigo
* ORCID logo ,
Amaya Pérez del Palomar
ORCID logo ,
Alberto Montolío
ORCID logo ,
Silvia Mendez-Martinez
,
Manuel Subias
ORCID logo ,
Maria Jose Cardiel
,
Teresa Martinez-Rincon
ORCID logo ,
José Cegoñino
,
Jose M. Fraile
ORCID logo ,
Eugenio Vispe
,
José Mayoral
,
Vicente Polo
,
Elena Garcia-Martin
Version 1 : Received: 30 November 2020 / Approved: 30 November 2020 / Online: 30 November 2020 (20:25:24 CET)

A peer-reviewed article of this Preprint also exists.

Rodrigo, M.J.; Palomar, A.P.; Montolío, A.; Mendez-Martinez, S.; Subias, M.; Cardiel, M.J.; Martinez-Rincon, T.; Cegoñino, J.; Fraile, J.M.; Vispe, E.; Mayoral, J.A.; Polo, V.; Garcia-Martin, E. Monitoring New Long-Lasting Intravitreal Formulation for Glaucoma with Vitreous Images Using Optical Coherence Tomography. Pharmaceutics 2021, 13, 217. Rodrigo, M.J.; Palomar, A.P.; Montolío, A.; Mendez-Martinez, S.; Subias, M.; Cardiel, M.J.; Martinez-Rincon, T.; Cegoñino, J.; Fraile, J.M.; Vispe, E.; Mayoral, J.A.; Polo, V.; Garcia-Martin, E. Monitoring New Long-Lasting Intravitreal Formulation for Glaucoma with Vitreous Images Using Optical Coherence Tomography. Pharmaceutics 2021, 13, 217.

Abstract

Intravitreal injection is the gold standard therapeutic option for posterior segment pathologies, and long-lasting release is necessary to avoid reinjections. There is no effective intravitreal treatment for glaucoma or other optic neuropathies in daily practice, nor is there a non-invasive method to monitor drug levels in the vitreous. Here we show that a glaucoma treatment combining a hypotensive and neuroprotective intravitreal formulation (IF) of brimonidine-Laponite (BRI/LAP) can be monitored non-invasively using vitreous imaging captured with optical coherence tomography (OCT) over 24 weeks of follow-up. Qualitative and quantitative characterization was achieved by analysing the changes in vitreous (VIT) signal intensity, expressed as a ratio of retinal pigment epithelium (RPE) intensity. Vitreous hyperreflective aggregates mixed in the vitreous and tended to settle on the retinal surface. Relative intensity and aggregate size progressively decreased over 24 weeks in treated rat eyes as the BRI/LAP IF degraded. VIT/RPE relative intensity and total aggregate area correlated with brimonidine levels measured in the eye. The OCT-derived VIT/RPE relative intensity may be a useful and objective marker for non-invasive monitoring of BRI/LAP IF.

Keywords

Keywords: Brimonidine; Laponite; drug delivery; glaucoma; nanomedicine; monitoring; optical coherence tomography; vitreous; intravitreal.

Subject

Medicine and Pharmacology, Immunology and Allergy

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.